SI2890397T1 - Formulacije protiteles proti receptorju za prolaktin - Google Patents
Formulacije protiteles proti receptorju za prolaktinInfo
- Publication number
- SI2890397T1 SI2890397T1 SI201331499T SI201331499T SI2890397T1 SI 2890397 T1 SI2890397 T1 SI 2890397T1 SI 201331499 T SI201331499 T SI 201331499T SI 201331499 T SI201331499 T SI 201331499T SI 2890397 T1 SI2890397 T1 SI 2890397T1
- Authority
- SI
- Slovenia
- Prior art keywords
- receptor antibody
- antibody formulations
- prolactin receptor
- prolactin
- formulations
- Prior art date
Links
- 230000001263 anti-prolactin effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261695949P | 2012-08-31 | 2012-08-31 | |
US13/842,906 US8883979B2 (en) | 2012-08-31 | 2013-03-15 | Anti-prolactin receptor antibody formulations |
EP13760180.3A EP2890397B1 (en) | 2012-08-31 | 2013-08-28 | Anti-prolactin receptor antibody formulations |
PCT/US2013/056976 WO2014036076A1 (en) | 2012-08-31 | 2013-08-28 | Anti-prolactin receptor antibody formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2890397T1 true SI2890397T1 (sl) | 2019-11-29 |
Family
ID=49162240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201331499T SI2890397T1 (sl) | 2012-08-31 | 2013-08-28 | Formulacije protiteles proti receptorju za prolaktin |
Country Status (30)
Country | Link |
---|---|
US (4) | US8883979B2 (sl) |
EP (1) | EP2890397B1 (sl) |
JP (1) | JP6444871B2 (sl) |
KR (1) | KR102100282B1 (sl) |
CN (3) | CN111202844A (sl) |
AR (2) | AR092387A1 (sl) |
AU (1) | AU2013308907B2 (sl) |
BR (1) | BR112015004397B1 (sl) |
CA (1) | CA2883097C (sl) |
CY (1) | CY1121990T1 (sl) |
DK (1) | DK2890397T3 (sl) |
ES (1) | ES2742868T3 (sl) |
HK (1) | HK1207316A1 (sl) |
HR (1) | HRP20191199T1 (sl) |
HU (1) | HUE045494T2 (sl) |
IL (1) | IL237277B (sl) |
IN (1) | IN2015DN02255A (sl) |
LT (1) | LT2890397T (sl) |
MX (1) | MX367691B (sl) |
NZ (1) | NZ705178A (sl) |
PL (1) | PL2890397T3 (sl) |
PT (1) | PT2890397T (sl) |
RS (1) | RS59207B1 (sl) |
RU (1) | RU2649372C2 (sl) |
SG (1) | SG11201501225SA (sl) |
SI (1) | SI2890397T1 (sl) |
TW (3) | TW201422235A (sl) |
UY (2) | UY34994A (sl) |
WO (1) | WO2014036076A1 (sl) |
ZA (1) | ZA201501279B (sl) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140135233A (ko) | 2012-03-14 | 2014-11-25 | 리제너론 파마슈티칼스 인코포레이티드 | 다중특이성 항원-결합 분자 및 그것의 용도 |
LT2935331T (lt) | 2012-12-24 | 2018-06-25 | Abbvie Inc. | Prolaktino receptorių surišantys baltymai ir jų panaudojimas |
JP2016515515A (ja) * | 2013-03-15 | 2016-05-30 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | 抗プロラクチン受容体抗体製剤 |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
CN107249571B (zh) * | 2015-02-09 | 2021-03-12 | Ucb生物制药私人有限公司 | 药物制剂 |
MX2017017117A (es) | 2015-07-06 | 2018-03-06 | Regeneron Pharma | Moleculas multiespecificas de union a antigenos y usos de estas. |
WO2017031288A1 (en) | 2015-08-19 | 2017-02-23 | Medimmune, Llc | Stable anti-ifnar1 formulation |
TW201726111A (zh) * | 2015-09-30 | 2017-08-01 | 持田製藥股份有限公司 | 含高濃度抗體之液體製劑 |
WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
EP3548514A1 (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
WO2018179138A1 (ja) * | 2017-03-29 | 2018-10-04 | 持田製薬株式会社 | 抗体含有液体製剤 |
TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗-prlr抗體藥物軛合物(adc)及其用途 |
CA3061705A1 (en) | 2017-04-11 | 2018-10-18 | Kiniksa Pharmaceuticals, Ltd. | Stable anti-osmr antibody formulation |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
JP2020527552A (ja) | 2017-07-10 | 2020-09-10 | バイエル・ファルマ・アクティエンゲゼルシャフト | 男性型脱毛症および女性型脱毛症用のプロラクチン受容体抗体 |
CN111356471A (zh) * | 2017-11-20 | 2020-06-30 | 济世发展生物药业有限公司 | 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途 |
MX2020008274A (es) | 2018-02-07 | 2020-11-11 | Regeneron Pharma | Metodos y composiciones para la administracion de proteinas terapeuticas. |
WO2020053321A1 (en) * | 2018-09-13 | 2020-03-19 | F. Hoffmann-La Roche Ag | Csf-1r antibody formulation |
JP7467438B2 (ja) * | 2018-10-18 | 2024-04-15 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗rsv抗体の製剤及びその使用方法 |
KR20210084533A (ko) * | 2018-10-30 | 2021-07-07 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨증 (pnh)의 치료를 위한 항-c5 항체의 피하 투여량 및 투여 |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
WO2023230532A1 (en) * | 2022-05-26 | 2023-11-30 | Compugen Ltd. | Anti-tigit antibody formulation |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
WO2001024814A1 (en) | 1999-10-04 | 2001-04-12 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
DK1507556T3 (en) | 2002-05-02 | 2016-09-12 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
PL207018B1 (pl) | 2002-06-21 | 2010-10-29 | Novo Nordisk Helth Care Ag | Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII |
CN1751236A (zh) * | 2002-12-16 | 2006-03-22 | 健泰科生物技术公司 | 表达人cd20的转基因小鼠 |
EP3777880A1 (en) | 2003-02-10 | 2021-02-17 | Biogen MA Inc. | Immunoglobulin formulation and method of preparation thereof |
KR101204712B1 (ko) | 2003-03-18 | 2012-11-27 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Gla-잔기 함유 세린 프로테아제의 제조 방법 |
RU2005132164A (ru) | 2003-03-18 | 2006-06-10 | Ново Нордиск Хелт Кэр Аг (Ch) | Жидкие, водные фармацевтические композиции полипептидов фактора vii |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR101441358B1 (ko) | 2003-05-14 | 2014-09-24 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
MXPA05012476A (es) | 2003-05-23 | 2006-02-22 | Novo Nordisk Healthcare Ag | Estabilizacion de proteina en solucion. |
ES2382157T3 (es) | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
ES2335994T3 (es) | 2003-07-01 | 2010-04-07 | Novo Nordisk Health Care Ag | Composicion farmaceutica liquida, acuosa de polipeptidos factor vii. |
KR101293503B1 (ko) | 2003-08-14 | 2013-08-07 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 vii 폴리펩티드의 액상 수성 약학적 조성물 |
EP3006463A1 (en) | 2003-10-01 | 2016-04-13 | Kyowa Hakko Kirin Co., Ltd. | Method for stabilizing antibody and stabilized solution-type antibody preparation |
DE10361599A1 (de) | 2003-12-24 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Flüssigformulierung von Antikörperkonjugaten |
US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
DE102004022927A1 (de) | 2004-05-10 | 2005-12-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten |
US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
WO2006014965A2 (en) | 2004-07-27 | 2006-02-09 | Human Genome Sciences, Inc. | Pharmaceutical formulation and process |
TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008519032A (ja) * | 2004-11-03 | 2008-06-05 | キュラジェン コーポレイション | Fgf−20の調合物、生成方法および使用 |
DE102005002353A1 (de) * | 2005-01-18 | 2006-07-27 | Abbott Gmbh & Co. Kg | AGER-Rezeptor Multimerisierungs Epitope |
US20080311078A1 (en) | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
WO2007002543A2 (en) * | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
CA2612937C (en) | 2005-07-22 | 2014-05-06 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
US8258256B2 (en) | 2006-01-05 | 2012-09-04 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
CA2642270A1 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Antibody formulation |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
CA2661023C (en) * | 2006-08-18 | 2017-08-15 | Novartis Ag | Prlr-specific antibody and uses thereof |
JP2010504361A (ja) | 2006-09-25 | 2010-02-12 | メディミューン,エルエルシー | 安定した抗体製剤およびその使用 |
EP2094729A1 (en) * | 2006-12-11 | 2009-09-02 | F.Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
AU2007338791B2 (en) | 2006-12-21 | 2014-03-13 | Amgen Inc | Stable buffered formulations containing polypeptides |
US20100143326A1 (en) | 2007-01-03 | 2010-06-10 | Novo Nordisk Healthcare A/G | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES |
CA2685372A1 (en) | 2007-05-02 | 2008-11-13 | F. Hoffmann-La Roche Ag | Method for stabilizing a protein |
EP2173163A4 (en) | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
JP2010536786A (ja) | 2007-08-17 | 2010-12-02 | アムジエン・インコーポレーテツド | ポリカチオンを用いた抗体およびfc融合分子の製剤 |
US8383114B2 (en) | 2007-09-27 | 2013-02-26 | Amgen Inc. | Pharmaceutical formulations |
JP5490714B2 (ja) | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
TWI661833B (zh) | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
EP2247307A1 (en) * | 2007-12-21 | 2010-11-10 | GlaxoSmithKline Biologicals S.A. | Vaccine |
BRPI0820819B1 (pt) * | 2007-12-21 | 2021-06-08 | F. Hoffmann-La Roche Ag | formulação de anticorpos humanizados b-ly 1 e seu uso |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
WO2009092758A1 (en) | 2008-01-23 | 2009-07-30 | Novo Nordisk Health Care Ag | New blood coagulation factor inhibitors |
PE20120169A1 (es) | 2008-11-17 | 2012-02-29 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
EP2332995A1 (en) | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
KR20120130757A (ko) | 2010-02-26 | 2012-12-03 | 노보 노르디스크 에이/에스 | 안정한 항체 함유 조성물 |
EP3733711A1 (en) * | 2010-10-06 | 2020-11-04 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
-
2013
- 2013-03-15 US US13/842,906 patent/US8883979B2/en active Active
- 2013-08-28 IN IN2255DEN2015 patent/IN2015DN02255A/en unknown
- 2013-08-28 AU AU2013308907A patent/AU2013308907B2/en active Active
- 2013-08-28 WO PCT/US2013/056976 patent/WO2014036076A1/en active Application Filing
- 2013-08-28 MX MX2015002412A patent/MX367691B/es active IP Right Grant
- 2013-08-28 LT LTEP13760180.3T patent/LT2890397T/lt unknown
- 2013-08-28 KR KR1020157007725A patent/KR102100282B1/ko active IP Right Grant
- 2013-08-28 RU RU2015111319A patent/RU2649372C2/ru active
- 2013-08-28 JP JP2015529978A patent/JP6444871B2/ja active Active
- 2013-08-28 PL PL13760180T patent/PL2890397T3/pl unknown
- 2013-08-28 SG SG11201501225SA patent/SG11201501225SA/en unknown
- 2013-08-28 CN CN201910972236.4A patent/CN111202844A/zh active Pending
- 2013-08-28 EP EP13760180.3A patent/EP2890397B1/en active Active
- 2013-08-28 RS RSP20190823 patent/RS59207B1/sr unknown
- 2013-08-28 CA CA2883097A patent/CA2883097C/en active Active
- 2013-08-28 CN CN201910972059.XA patent/CN111202843A/zh active Pending
- 2013-08-28 BR BR112015004397-6A patent/BR112015004397B1/pt active IP Right Grant
- 2013-08-28 HU HUE13760180A patent/HUE045494T2/hu unknown
- 2013-08-28 PT PT13760180T patent/PT2890397T/pt unknown
- 2013-08-28 US US14/421,609 patent/US20150252116A1/en not_active Abandoned
- 2013-08-28 CN CN201380053890.6A patent/CN104736175B/zh active Active
- 2013-08-28 NZ NZ705178A patent/NZ705178A/en unknown
- 2013-08-28 SI SI201331499T patent/SI2890397T1/sl unknown
- 2013-08-28 ES ES13760180T patent/ES2742868T3/es active Active
- 2013-08-28 DK DK13760180.3T patent/DK2890397T3/da active
- 2013-08-29 AR ARP130103084A patent/AR092387A1/es unknown
- 2013-08-29 TW TW102131090A patent/TW201422235A/zh unknown
- 2013-08-29 UY UY0001034994A patent/UY34994A/es not_active Application Discontinuation
- 2013-08-30 UY UY0001034999A patent/UY34999A/es not_active Application Discontinuation
- 2013-08-30 AR ARP130103100A patent/AR092401A1/es not_active Application Discontinuation
- 2013-08-30 TW TW106132855A patent/TWI688404B/zh active
- 2013-08-30 TW TW102131178A patent/TWI641384B/zh active
-
2014
- 2014-09-30 US US14/501,986 patent/US20150093393A1/en not_active Abandoned
-
2015
- 2015-02-17 IL IL237277A patent/IL237277B/en active IP Right Grant
- 2015-02-25 ZA ZA2015/01279A patent/ZA201501279B/en unknown
- 2015-08-20 HK HK15108067.4A patent/HK1207316A1/xx unknown
-
2016
- 2016-09-27 US US15/276,794 patent/US20170008965A1/en not_active Abandoned
-
2019
- 2019-07-02 HR HRP20191199TT patent/HRP20191199T1/hr unknown
- 2019-08-16 CY CY20191100880T patent/CY1121990T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207316A1 (en) | Anti-prolactin receptor antibody formulations | |
HK1203146A1 (en) | Antibody formulation | |
HK1203191A1 (en) | P2x4 receptor antagonist p2x4 | |
HK1201857A1 (en) | Antibody formulations | |
RS59221B1 (sr) | Formulacije antitela | |
GB201213700D0 (en) | Receptor antagnists II | |
HK1215175A1 (zh) | 抗-催乳素受體抗體製劑 | |
HK1207985A1 (en) | Somatostatin receptor agonist formulations | |
IL244356B (en) | Formulations for cgrp receptor antagonists | |
HK1210182A1 (en) | Anti-prokineticin receptor (prokr) antibodies and uses thereof (prokr) | |
GB201223053D0 (en) | Receptor | |
GB201213698D0 (en) | Receptor antagonists II | |
GB201213699D0 (en) | Receptor antagonists II |